Natco Pharma Ltd.

BSE: 524816 | NSE: NATCOPHARM
Small Cap | Pharmaceuticals & Drugs
923.65
5.75 (0.63%)
< Home < Back

Natco Pharma soars as its US marketing partner receives USFDA approval for Armodafinil Tablets

Date: 21-10-2014

Natco Pharma is currently trading at Rs. 1329.00, up by 67.40 points or 5.34% from its previous closing of Rs. 1261.60 on the BSE.

The scrip opened at Rs. 1277.55 and has touched a high and low of Rs. 1335.00 and Rs. 1276.55 respectively. So far 8551 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1585.70 on 16-Sep-2014 and a 52 week low of Rs. 650.00 on 29-Oct-2013.

Last one week high and low of the scrip stood at Rs. 1424.20 and Rs. 1245.40 respectively. The current market cap of the company is Rs. 4289.58 crore.

The promoters holding in the company stood at 53.52% while Institutions and Non-Institutions held 24.47% and 22.02% respectively.

Natco Pharma’s marketing partner in the USA, Breckenridge Pharmaceutical, Inc. (BPI), has received a tentative approval from the United States Food & Drug Administration (USFDA) for Armodafinil 50mg, 150mg, and 250mg Tablets.

Breckenridge filed the Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to obtain approval to engage in the commercial manufacture, use and sale of its generic to Nuvigil prior to expiration of the listed patents. Natco and Breckenridge have entered into a settlement regarding the ANDA with Cephalon, the terms of which are confidential. Cephalon has granted Natco and Breckenridge a license to market generic versions of the 50mg, 100 mg, 150mg, 200 mg and 250mg strengths of Nuvigil, beginning 180-days after the initial launch of these strengths.

Cephalon (acquired by Teva in 2011) sells Armodafinil 50mg, 150mg, and 250mg Tablets under Brand name Nuvigil in the USA market. Nuvigil is a wakefulness promoting agent for oral administration. The market size of Nuvigil in the USA is approximately $457 million for twelve months ending August 2014, according to IMS Health.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.